Q-omics provides the consensus-scored AKT1 profile across patient tissues and cancer cell-line models. AKT1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, AKT1 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, AKT1 RNA expression shows 19,457 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, and ACC as cancer lineages where AKT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AKT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AKT1 survival associations across molecular data types. AKT1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AKT1 RNA expression–survival associations across cancer types. High AKT1 expression shows unfavorable associations in HNSC, ACC, KIRP and MESO, but favorable associations in KIRC and OV. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for AKT1 RNA expression.
This table summarizes AKT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for AKT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AKT1 shows higher tumor expression in HNSC, BRCA, COAD, UCEC, STAD and CHOL. The HNSC box plot shows higher AKT1 RNA expression in tumor versus normal tissue (log2 FC = +1.041, t-test p < 0.001).
This table shows molecular features associated with AKT1 in patient tissues and cancer cell lines. In patient samples, AKT1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, AKT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
